Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Common Equity: 2013-2025

Historic Common Equity for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $776.7 million.

  • Amphastar Pharmaceuticals' Common Equity rose 6.74% to $776.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $776.7 million, marking a year-over-year increase of 6.74%. This contributed to the annual value of $732.3 million for FY2024, which is 14.53% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Common Equity stood at $776.7 million for Q3 2025, which was up 2.54% from $757.5 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Common Equity peaked at $776.7 million during Q3 2025, and registered a low of $430.2 million during Q3 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Common Equity averaged around $682.1 million, with its median value being $713.3 million (2024).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Common Equity fell by 4.61% in 2021, and later increased by 22.56% in 2024.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Common Equity stood at $445.5 million in 2021, then grew by 18.66% to $528.7 million in 2022, then increased by 20.95% to $639.4 million in 2023, then climbed by 14.53% to $732.3 million in 2024, then climbed by 6.74% to $776.7 million in 2025.
  • Its last three reported values are $776.7 million in Q3 2025, $757.5 million for Q2 2025, and $751.3 million during Q1 2025.